Last reviewed · How we verify
Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies
Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies
Details
| Lead sponsor | Chinese PLA General Hospital |
|---|---|
| Phase | PHASE2 |
| Status | NOT_YET_RECRUITING |
| Enrolment | 90 |
| Start date | Tue Mar 03 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Oct 30 2028 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Treatment for Advanced Colorectal Cancer
- Treatment for Advanced Pancreatic Cancer
Interventions
- Colorectal cancer: Tunlametinib + cetuximab β
- Pancreatic cancer: Tunlametinib + cetuximab β
- Pancreatic cancer: Tunlametinib +Nimotuzumab